US Patent Issued to Nurix Therapeutics, Gilead Sciences on Jan. 20 for "Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof" (California Inventors)

ALEXANDRIA, Va., Jan. 20 -- United States Patent no. 12,528,814, issued on Jan. 20, was assigned to Nurix Therapeutics Inc. (San Francisco) and Gilead Sciences Inc. (Foster City, Calif.).

"Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof" was invented by Wylie Solang Palmer (San Francisco), Jeffrey Wu (San Francisco), Sheila Zipfel (Foster City, Calif.), Kerem Ozboya (San Francisco) and Dahlia Weiss (San Francisco).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4."

The patent was filed on Feb. 19, 2021, und...